MedTrace Logo

Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE

NCT07722780 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2026-07-23

No results posted yet for this study

Summary

This trial adopted a multicenter, randomized, double-blind, placebo-controlled design and consisted of two parts: Part Ⅰ and Part Ⅱ.

Conditions

  • Premature Ejaculation

Interventions

DRUG

VV913 2mg Capsules

VV913 2mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

DRUG

VV913 5mg Capsules

VV913 5mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

DRUG

VV913 10mg Capsules

VV913 10mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

DRUG

Placebo

VV913 Placebo Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Hui Jiang · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07722780 on ClinicalTrials.gov